Insider · CIK 0001709418
John A Stalfort III
director
Files at ABOS (Acumen Pharmaceuticals, Inc.), VRCA (Verrica Pharmaceuticals Inc.), TSHA (Taysha Gene Therapies, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,800 | $0.00 | $0 | 185,124 | Jun 5, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Jun 5, 2025 |
| Jun 2, 2025 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock | +56,623 | $0.00 | $0 | 1,155,224 | Jun 4, 2025 |
| Jun 2, 2025 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Stock Option (right to buy)derivative | +113,246 | $0.00 | $0 | 113,246 | Jun 4, 2025 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Common Stock | +1,123,595 | - | - | 1,823,800 | Nov 26, 2024 |
| Nov 26, 2024 | VRCA Verrica Pharmaceuticals Inc. | GGift Common Stock | +50,000 | $0.00 | $0 | 1,873,800 | Nov 26, 2024 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Series A Warrants (right to buy)derivative | +561,797 | - | - | 561,797 | Nov 26, 2024 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Series B Warrants (right to buy)derivative | +561,797 | - | - | 561,797 | Nov 26, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.